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Aims b-catenin has been shown to be regulated by inducible nitric oxide synthase (NOS) in endothelial cells. We investigated
here whether b-catenin interacts with and regulates endothelial NOS (eNOS) and whether eNOS activation promotes
b-catenin signalling.
Methods
and results
We identified b-catenin as a novel eNOS binding protein in human umbilical vein endothelial cells (HUVECs) by mass
spectroscopy and western blot analyses ofb-catenin and eNOS immunoprecipitates. This was confirmed by in situ prox-
imity ligationassay. eNOS activity, assessed by cGMP production and eNOS phosphorylation (Ser1177), wasenhanced in
b-catenin2/2 mouse pulmonary endothelial cells (MPECs) relative to wild-type MPECs. eNOS activation (using adeno-
sine, salbutamol, thrombin, or histamine), or application of an NO donor (spermine NONOate) or cGMP-analogue
(8-bromo-cGMP) caused nuclear translocation ofb-catenin in HUVEC as shown by western blotting of nuclear extracts.
Exposure to spermine NONOate, 8-bromo-cGMP, or sildenafil (a phosphodiesterase type 5 inhibitor) also increased the
expression ofb-catenin-dependent transcripts, IL-8, and cyclin D1. Stimulation of wild-type MPECs with basic fibroblast
growth factor (bFGF), vascular endothelial growth factor (VEGF), spermine NONOate, 8-bromo-cGMP, or sildenafil
increased tube length relative to controls in an angiogenesis assay. These responses were abrogated in b-catenin2/2
MPECs,with theexception of that tobFGFwhich isNO-independent. In C57BL/6mice, subcutaneous VEGF-supplemen-
ted Matrigel plugs containingb-catenin2/2MPECs exhibited reduced angiogenesis compared with plugs containing wild-
type MPECs. Angiogenesis was not altered in bFGF-supplemented Matrigel.
Conclusion These data reveal bidirectional cross-talk and regulation between the NO-cGMP and b-catenin signalling pathways.
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1. Introduction
Nitric oxide (NO), generated by the vascular endothelium through the
action of endothelial NO synthase (eNOS), plays an essential part in vas-
cular homeostasis, principally through causing vasodilation and inhibiting
platelet function, thrombogenesis, vascular smooth muscle cell prolifer-
ation, and progression of atherosclerosis.1,2 Classically, eNOS is activated
through an increase in cytosolic Ca2+ and consequent binding of Ca2+-
calmodulin.3 However, it is now apparent that activation can also occur
independentlyof any rise incytosolicCa2+, viaphosphorylationonspecific
residues and/or association with proteins such as b-actin,4 heat shock
protein-90, caveolin-1, and dynamin-2, as previously reviewed.5
Recently, inducible NOS (iNOS) has been demonstrated to regulate
the function of b-catenin, a key component of the endothelial adherens
† These authors contributed equally to the work.
‡ Present address: Department of Colorectal Surgery, Peking University Cancer Hospital & Beijing Institute of Cancer Research, Beijing, China.
* Corresponding author. Tel: +44 20 7848 4283; fax: +44 20 7848 4500, Email: albert.ferro@kcl.ac.uk
& The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
Cardiovascular Research (2014) 104, 116–126
doi:10.1093/cvr/cvu173
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/article-abstract/104/1/116/317076 by R
oyal Veterinary C
ollege user on 15 August 2019
junction, in endothelial cells.6 Furthermore, in MLO-Y4 osteocytes, NO
has been shown to activate the b-catenin signalling pathway;7 and a
recent study reported that NO increases endothelial permeability
through S-nitrosylation of b-catenin in response to vascular endothelial
growth factor (VEGF).8
Aside from its importance in the regulation of permeability,b-catenin
in concert with T-cell factor/lymphocyte enhancing factor (TCF/LEF)
transcription factors, also plays an important role in transcriptional regu-
lation of various genes and is a key modulator in the Wnt signalling
pathway.9 b-catenin target genes include c-Myc10 cyclin D11 and
axin-2,12 as well as the sox (sox-9, sox-17) and matrix metalloproteinase
(MMP-2, MMP-9, MMP-7) families.13– 16 NO has also long been known
to regulate downstream gene expression. As examples, activity of the
transcription factor c-jun is inhibited by NO,17 and NF-kB activity is
down-regulated due to NO-induced S-nitrosylation.18 A potential link
between transcriptional regulation by NO and b-catenin has been
revealed in conditionally immortalized murine colonic epithelial cells,
where the NO donor NOR-1 was reported to induceb-catenin associ-
ation with LEF in the nucleus.19
We hypothesized that endothelium-derived NO may induceb-catenin
to translocate from the cytosol and/or plasmalemma of endothelial cells
to the nucleus, thereby inducing changes in gene transcription. The aims
of this study were three-fold: first to investigate whether b-catenin inter-
actsdirectlywitheNOSinendothelial cells; secondly toascertainwhether
such interaction modulates eNOS activity; and thirdly to determine
whether activation of NO-cGMP signalling—either through endogenous
eNOS stimulation or through other means—gives rise to nuclear trans-
location of b-catenin with resultant gene transcriptional and functional
effects.
2. Methods
Detailed methods are available in the Supplementary material online.
2.1 Cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated as pre-
viously described.20 Wild-type and b-catenin2/2 mouse pulmonary endo-
thelial cells (MPECs) were a generous gift from Professor Elisabetta Dejana,
University of Milan, Italy.21
2.2 Proximity ligation assay
HUVECs cultured in 16-well chamber slides (30 000 cells/well) were fixed
with 4% paraformaldehyde then permeabilized with 0.5% TX-100. In situ
proximity ligation assay (PLA) was carried out using rabbit anti-eNOS and
mouse anti-b-catenin primary antibodies in combination with Duolink
In Situ Red Detection Kit (Sigma). PLA was carried out according to the
manufacturer’s instructions.
2.3 Preparation of lysates
Cell lysates were prepared as previously described.20 For preparation of
nuclear lysates, hypotonic buffer followed by centrifugation was used to
collect the cytosolic fraction (supernatant). Pellets (containing the nuclei)
were lysed with high-salt buffer.
2.4 Immunoprecipitation and western blotting
Immunoprecipitation of eNOS or b-catenin from 400 mg of cell lysate with
1 mg of antibody was carried out as previously described using Protein G
Sepharose beads. Electrophoresis and electroblotting were performed as
described.4
2.5 cGMP ELISA
MPEC lysates were extracted in the presence of 3-isobutyl-1-methyl-
xanthine (IBMX; 1 mmol/L) by addition of 0.1 mol/L HCl. cGMP concentra-
tion was assessed following acetylation using Cyclic GMP EIA Kit (Cayman
Chemicals) according to the manufacturer’s instructions. Resulting cGMP
concentrations were normalized to protein content per sample.
2.6 Angiogenesis assays
To evaluate angiogenesis (tube formation) in vitro, MPECs were seeded onto
Matrigel; total tube length was assessed after 6 h. To investigate in vivo angio-
genesis, Matrigel supplemented with either VEGF or basic fibroblast growth
factor (bFGF) was mixed with MPECs loaded with VybrantwDiO cell label-
ling solution (Life Technologies) and injected into C57BL/6 mice anaesthe-
tized using isoflurane. Following sacrifice, plugs were excised, snap-frozen,
and cryosectioned for immunostaining with an anti-CD31 antibody and
imaged by confocal microscopy. Capillary formation was assessed by deter-
mining the percentage of CD31-positive Vybrant-labelled MPECs compared
with the total number of CD31-positive cells within four randomly selected
fields of view per plug. Animals were studied in accordance with Directive
2010/63/EU of the European Parliament.
2.7 Quantitative RT–PCR
RNA was isolated using QIAGEN RNeasy Kit according to the manufac-
turer’s instructions. Transcript levels were assessed by quantitative real-time
PCR using gene-specific primers.
2.8 Statistical analysis
All data are presented as mean+ SEM. Statistical analysis was performed
using GraphPad Prism (Version 6.0) software. Unless indicated otherwise,
all statistical comparisons were by one-way analysis of variance (ANOVA)
with repeated measures and the Geisser-Greenhouse correction for spher-
icity. Fisher’s LSD test was used for planned post-hoc pairwise comparisons.
Two-way ANOVA was carried out where inhibitors were used in conjunc-
tion with agonists. Where responses of wild-type and b-catenin2/2
MPECs were examined, responses within each cell type were analysed sep-
arately by ANOVA as appropriate. In all cases, P, 0.05 (two-sided) was
taken to indicate statistical significance.
3. Results
3.1 b-catenin associates with eNOS in
HUVEC
To investigate whether b-catenin associates with eNOS, eNOS was
immunoprecipitated from HUVEC lysates, and the resulting immuno-
precipitates were subjected to western blotting for both eNOS and
b-catenin (Figure 1A). Immunoprecipitation of eNOS resulted in the de-
tection of both eNOS andb-catenin, and similarly immunoprecipitation
of b-catenin resulted in the detection of both proteins. The association
between eNOS andb-catenin was confirmed in situ in fixed cells by PLA
(Figure 1B). Amplification products were detected in HUVEC exposed
to both eNOS and b-catenin antibodies, indicative of close proximity
(,40 nm) of the two proteins; in contrast, controls where antibodies
were omitted or used individually did not yield amplification products.
Furthermore, peptide mass fingerprinting confirmed the presence of
b-catenin in eNOS immunoprecipitates (Supplementary material
online, Figure S1).
3.2 b-catenin regulates eNOS activity
Todeterminewhetherb-catenin binding toeNOS mayserve to regulate
eNOS function, we first measured intracellular cGMP, a well-validated
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index of bioactive NO, in wild-type and b-catenin2/2 MPECs. The
absence of b-catenin protein in b-catenin2/2 MPECs was confirmed
by western blotting (Supplementary material online, Figure S2). cGMP
was higher in b-catenin2/2 compared with wild-type MPECs
(Figure 2A). We next assessed eNOS phosphorylation status on
Ser1177, a sensitive index of eNOS activity, by western blotting of cell
lysates using an antibody that specifically recognizes phosphoSer-1177-
modified eNOS; this was performed both on unstimulated and stimu-
lated (with adenosine or histamine, each at 100 mmol/L for 2.5 min)
wild-type and b-catenin2/2 MPECs. Stimulation with either agent
increased eNOS phosphorylation in wild-type MPECs, and this was
abrogated by pre-treatment with Akt inhibitor IV (10 mmol/L; Calbio-
chem). Moreover, we found thatb-catenin2/2 MPECs exhibited signifi-
cantly higher levels of eNOS phosphorylation under non-stimulated
conditions, which were only partially reduced by the Akt inhibitor,
and that stimulation of these cells with adenosine or histamine did not
produce any further rise in eNOS phosphorylation (Figure 2B). These
data suggest that b-catenin may function as an endogenous negative
regulator of eNOS in endothelial cells.
3.3 Pharmacological activation of eNOS
reduces association with b-catenin
Having demonstrated that b-catenin associates with, and tonically inhi-
bits, eNOS activity in unstimulated cells we sought to determine, using
PLA, whether the interaction is maintained following pharmacological
activation of eNOS. Amplification products were observed throughout
the cell and localized close to cell borders in vehicle-treated HUVECs;
however, following stimulation for 2.5 min with adenosine (100 mmol/
L), salbutamol (1 mmol/L), histamine (100 mmol/L), or thrombin (1 IU/
mL), few amplification products were observed, suggesting a loss of
interaction between eNOS and b-catenin following eNOS activation
(Figure 2C).
Figure 1 eNOS and b-catenin are associated in HUVECs. (A) HUVEC lysates were immunoprecipitated (IP) using either anti-eNOS or anti-b-catenin
antibody, or corresponding control antibodies (mouse IgGor rabbit IgG, respectively), followed bywesternblotting to probe foreithereNOS orb-catenin.
IP of either protein resulted in detection of the other (experiment shown is representative of n ¼ 3). (B) HUVECs were fixed and subject to PLA using
antibodies targeting eNOS and b-catenin (images IV–VI). Amplification products are observed throughout the cells, particularly at cell borders. In
control samples where PLA was carried out in the absence of antibodies (I), or b-catenin (II) or eNOS antibody (III) were used alone, no amplification
products were observed. Scale bar shows 50 mm.
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Figure 2 Loss of b-catenin increases basal eNOS phosphorylation and cGMP production. (A) cGMP production was assessed in wild-type and
b-catenin2/2 MPECs by ELISA and results expressed relative to protein content per sample (shown relative to wild-type; *P, 0.05, unpaired t-test,
n ¼ 4 per group). (B) Wild-type and b-catenin2/2 MPECs were treated with adenosine (100 mmol/L), histamine (100 mmol/L), or vehicle for 2.5 min
in the presenceorabsenceof Akt inhibitor (10 mmol/L; pre-treatment for 30 min).B(i), Cell lysateswereprobed by westernblotting for phosphoSer-1177-
eNOS and total eNOS, and B(ii) results expressed as the densitometric ratio of phosphoSer-1177-eNOS/GAPDH to total eNOS/GAPDH (*P, 0.05 vs.
vehicle, #P, 0.05, ###P, 0.001 vs. corresponding treatment in the absence of Akt inhibitor; two-way ANOVA; n ¼ 6 per group). Wild-type vehicle vs.
b-catenin2/2 vehicle were analysed separately by unpaired t-test (**P, 0.01). (C) HUVECs were treated with adenosine (100 mmol/L), salbutamol
(1 mmol/L), histamine (100 mmol/L), thrombin (1 IU/mL), or vehicle for 2.5 min then fixed and subject to PLA using antibodies targeting eNOS and
b-catenin (II– IV). PLA was also carried out with the omission of primary antibodies (I). Images are representative of three independent cultures (scale
bar shows 50 mm). Images were quantified using ImageJ Particle Analyser to determine the number of PLA signal per image and expressed as the mean
number of signals per nucleus (*P, 0.05, **P, 0.01, one-way ANOVA with repeated measures, n ¼ 3 per group).
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3.4 Agents which activate eNOS and
NO-cGMP induce nuclear translocation
of b-catenin
Wenext determinedwhethereNOSstimulationorNO-cGMPpathway
activation by other means induces b-catenin to translocate to the
nucleus, an initial first step in its mediating effects on downstream
gene transcription. HUVECs were treated with adenosine (100 mmol/
L), salbutamol (1 mmol/L), histamine (100 mmol/L), or thrombin (1 IU/
mL)—all at concentrations which we have previously found to cause
maximal eNOS activation—or vehicle for 2.5 min, following which
cells were fixed and immunostained for b-catenin, and imaged by con-
focal microscopy. In vehicle-treated cells, b-catenin was found mainly
in the plasma membrane, in an even distribution, with minimal nuclear
staining. In contrast, treatment with any of the eNOS agonists caused
clear accumulation of b-catenin staining in the nuclear and/or peri-
nuclear region (Figure 3A), with no obvious change in plasmalemmal
staining.
To confirm that eNOS activation gives rise to accumulation of
b-catenin within the nucleus, HUVECs were treated as above and
nuclear proteins were extracted. Levels of nuclear b-catenin were
determined by western blotting of nuclear extracts, with normalization
to the nuclear membrane protein lamin A/C. All eNOS agonists tested
induced an increase of nuclearb-catenin (Figure 3B). However, whereas
the nuclear accumulation of b-catenin induced by adenosine and salbu-
tamol (whichdonot elevate cytosolicCa2+)was completely inhibitedby
the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME;
100 mmol/L), that induced by histamine and thrombin (which activate
eNOS by elevating cytosolic Ca2+) was not (Figure 3B). This suggests
that both NO and an elevated cytosolic Ca2+ can independently
induce translocation of b-catenin to the nucleus, the latter irrespective
of eNOS activation. Consistent with this, translocation of b-catenin to
the nucleus induced by the Ca2+ ionophore ionomycin (10 mmol/L)
was similarly unaffected by the presence of L-NAME (Figure 3B). Glyco-
gen synthase kinase (GSK)-3b phosphorylates b-catenin on Ser37 and
Thr41, promoting its ubiquitination and degradation.22 We therefore
also examined the effect of LiCl (which inhibits GSK-3b23) on nuclear
accumulation of b-catenin, as a positive control. As expected, LiCl
(10 mmol/L) increased nuclearb-catenin in HUVEC whichwasunaffect-
ed by co-incubation with L-NAME (Figure 3B).
We also examined whether eNOS, following its activation,
co-translocates to thenucleuswithb-catenin.Treatmentwith theCa2+-
elevating agonists, histamine and thrombin, induced nuclear transloca-
tion of eNOS (which was unaffected by co-incubation with L-NAME),
whereas treatment with adenosine and salbutamol did not (Supplemen-
tary material online, Figure S3). These results show that, although
b-catenin and eNOS co-associate in the plasma membrane, b-catenin
translocation to the nucleus following eNOS activation (at least by ago-
nists that do not raise intracellular Ca2+) does not require translocation
of eNOS.
On this basis, we hypothesized that eNOS-mediated translocation of
b-catenin to the nucleus was caused by NO production with conse-
quent activation of soluble guanylyl cyclase (sGC) and cGMP generation.
As elevation of cytosolic Ca2+ clearly activates a separate pathway (as
shown earlier), we used salbutamol (which activates eNOS without
elevating cytosolic Ca2+23) as the agonist. HUVECs were treated with
salbutamol for 2.5 min, in the presence or absence of either L-lysine
(1 mmol/L), which competes with L-arginine for transport into the
cell and suppresses Ca2+-independent activation of eNOS,23 or
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10 mmol/L), a
specific inhibitor of sGC. To directly determine the effects of cGMP
and NO, we also stimulated the cells with the cell-permeable cGMP ana-
logue, 8-bromo-cGMP (10 mmol/L), or the NO donor, spermine
NONOate (10 mmol/L), for 2.5 min. Consistent with the hypothesis
that NO and cGMP mediate translocation of b-catenin, the
salbutamol-induced elevation of nuclear b-catenin was abolished by
both L-lysine and ODQ, and both 8-bromo-cGMP and spermine
NONOate induced elevation of nuclear b-catenin (Figure 4A).
3.5 eNOS activation increases levels
of active (dephosphorylated) b-catenin
Nuclear translocation of b-catenin is typically associated with its activa-
tion, requiring dephosphorylation of Ser37 and Thr41. We examined ac-
tivation ofb-catenin using the clone 8E7 antibody (anti-ABC, Millipore),
which recognizes active b-catenin dephosphorylated on Ser37 and
Thr41.24 All four of the eNOS agonists tested induced an increase in
active b-catenin in whole cell lysates, with no change in total
b-catenin, as did LiCl which was used as a positive control (Figure 4B).
3.6 eNOS activation and NO inhibit GSK-3b
by activating cGMP-dependent protein
kinase
Having established a role for sGC activation and cGMP generation in
inducing translocation of b-catenin to the nucleus, we reasoned that
cGMP-dependent protein kinase (PKG) may be important in this
process by stabilizingb-catenin through phosphorylation (and hence in-
hibition) of GSK-3b.25 HUVECs were treated with adenosine (a Ca2+-
independent activator of eNOS23) or spermine NONOate for
2.5 min, in the presence or absence of either ODQ or the PKG inhibitor
Rp-8-bromo-guanosine 3′5′-cyclic monophosphorothioate (Rp;
10 mmol/L). Phosphorylation of GSK-3bwas assessed using an antibody
that recognizes GSK-3b phosphorylated on Ser9 (Cell Signaling Tech-
nology). Adenosine and spermine NONOate both increased the ratio
of phospho-GSK-3b/total GSK-3b, and these increases were abolished
by either ODQ or Rp. In contrast, although LiCl increased the
phospho-GSK-3b/total GSK-3b ratio, this was unaffected by either
ODQ or Rp (Figure 4C).
3.7 NO-cGMP pathway activation increases
expression of b-catenin target genes
To ascertain whether nuclear translocation of b-catenin induced by the
NO-sGC-cGMP pathway gives rise to transcriptional activation, we
assessed the expression of cyclin D111 and interleukin 8 (IL-8),26,27
which are b-catenin/TCF target genes involved in the regulation of
angiogenesis, 12 h after stimulation with spermine NONOate or the
phosphodiesterase inhibitor sildenafil (100 nmol/L). Both agents
increased expression of IL-8 (Figure 5A) and cyclin D1 (Figure 5B) relative
to vehicle, as did LiCl (included as a positive control).
3.8 NO-mediated angiogenesis is abrogated
in b-catenin2/2 mouse pulmonary
endothelial cells
NO-cGMP signalling plays a pivotal role in VEGF-induced angiogenesis,
acting as a downstream effector of VEGF,28– 30 and also regulating VEGF
expression.31,32 We hypothesized that, since NO and cGMP increase
transcriptional activity of b-catenin, loss of b-catenin may impair the
NO-mediated angiogenic response. We assessed the expression of
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VEGF in wild-type and b-catenin2/2 MPECs following stimulation for
12 h with spermine NONOate, 8-bromo-cGMP or sildenafil, by
western blotting of cell lysates. All three agents increased expression
of VEGF compared with vehicle in wild-type, but not b-catenin2/2,
MPECs (Figure 6A). A scratch-wound assay was performed to ascertain
the migratory capacity of wild-type and b-catenin2/2 MPECs in re-
sponse to stimulation (as discussed earlier), as well as to VEGF.
Wound closure was increased by all agents in wild-type MPECs relative
to vehicle, but not in b-catenin2/2 MPECs (Supplementary material
online, Figure S4A).
Angiogenesis (tube formation) was assessed in vitro by seeding MPECs
onto Matrigel following stimulation with VEGF, spermine NONOate,
8-bromo-cGMP, or sildenafil. Tube length was increased by all agents
in wild-type, but not b-catenin2/2, MPECs relative to vehicle
Figure 3 Activation of eNOS induces nuclear translocation ofb-catenin in HUVECs. (A) HUVECs were treated with vehicle (II), 100 mmol/L adenosine
(III), 1 mmol/L salbutamol (IV) 100 mmol/L histamine (V), or 1 IU/mL thrombin (VI) for 2.5 min, then fixed and immunostained for b-catenin (red). Cells
were mounted in medium containing DAPI (blue) and imaged using a confocal microscope. Samples were included where primary antibody was omitted to
control for non-specific binding of the secondary antibody (I). b-catenin was not observed in the nucleus of vehicle-treated cells, whereas all agonists eli-
cited accumulation ofb-catenin in the nuclear or peri-nuclear region. Images shown are representative of n ¼ 4 experiments. (B) HUVECs were treated as
above or with 10 mmol/L ionomycin or with 10 mmol/L LiCl, in the absence or presence of L-NAME (100 mmol/L), and nuclear extracts probed by western
blotting for b-catenin. Results are expressed as the densitometric ratio of b-catenin to lamin A/C (shown relative to vehicle). *P, 0.05, **P, 0.01,
***P, 0.01 vs. vehicle (two-way ANOVA; n ¼ 5–12 per group). Scale bar shows 50 mm.
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Figure4 eNOS activation and NO-cGMP induce nuclear translocation and activation ofb-catenin and inhibition of GSK-3b. (A) HUVECs were exposed
to salbutamol for 2.5 min, either in the absence or presence of L-lysine (Lys; 1 mmol/L) or ODQ (10 mmol/L), or to 8-bromo-cGMP (cGMP; 10 mmol/L) or
spermineNONOate (NO;10 mmol/L) for 2.5 min.Nuclearextractswere subjected towesternblotting forb-catenin and laminA/C.Results areexpressed
as the densitometric ratio of b-catenin to lamin A/C, and shown relative to vehicle (*P, 0.05, **P, 0.01 vs. vehicle, one-way ANOVA without repeated
measures, n ¼ 5–8 per group). (B) Following exposure to adenosine (Ade; 100 mmol/L), histamine (His; 100 mmol/L), salbutamol (Sal; 1 mmol/L), throm-
bin (Thr; 1 IU/mL) or LiCl (10 mmol/L) for 2.5 min, whole cell lysates were probed by western blotting for active and totalb-catenin. Results are expressed
as the ratio of active to total b-catenin (*P, 0.05, **P, 0.01 vs. vehicle, one-way ANOVA with repeated measures; n ¼ 4 per group). (C) HUVECs were
exposed to LiCl (10 mmol/L), adenosine (Ade; 100 mmol/L) or spermine NONOate (NO; 10 mmol/L) for 2.5 min, in the presence or absence of ODQ
(10 mmol/L) or Rp-8-bromo-guanosine 3′5′-cyclic monophosphorothioate (Rp; 10 mmol/L). Cell lysates were probed for total and phosphorylated
GSK-3b. All results are expressed as the densitometric ratio of phosphorylated-GSK-3b/GAPDH to total GSK-3b/GAPDH and shown relative to
vehicle (*P, 0.05, **P, 0.01 vs. vehicle, two-way ANOVA; n ¼ 5 per group).
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(Figure 6B). On the other hand both wild-type andb-catenin2/2 MPECs
exhibited increased tube length following stimulation with bFGF
(Supplementary material online, Figure S4B), an agent which stimulates
angiogenesis independently of NO-cGMP signalling.30
To determine whether loss of b-catenin affects NO-mediated angio-
genesis in vivo, a Matrigel plug assay was performed to assess capillary
formation in plugs containing fluorescent-labelled wild-type or
b-catenin2/2 MPECs in the presence of either VEGF or bFGF. In plugs
supplemented with bFGF, capillary formation (assessed by the number
of Vybrant-positive cells staining positive for CD31 as a percentage of
total CD31-positive cells to take into account cells migrated from
outside the plug) was similar between wild-type and b-catenin2/2
MPECs; however, in VEGF-supplemented plugs, b-catenin2/2 MPECs
exhibited less Vybrant-positive CD31-positive cells and lower
numbers of capillary-like structures or vascular networks compared
with wild-type MPECs (Figure 6C). In parallel experiments, Matrigel
was injected containing VEGF and either scrambled or b-catenin
siRNA. The efficacy of b-catenin siRNA to reduce b-catenin protein
levels was initially confirmed by western blotting of lysates following
transfection of wild-type MPECs. Plugs containing b-catenin siRNA
exhibited fewer CD31-positive cells per plug (indicating fewer endothe-
lial cells migrated into the plug from surrounding tissue) compared with
those containing non-targeting sequences (Supplementary material
online, Figure S5). These data suggest that angiogenesis, driven by NO
signalling, is attenuated following loss or knockdown of b-catenin.
4. Discussion
We here provide the first evidence that eNOS associates withb-catenin
in endothelial cells, and that this association serves as a negative regula-
tor of eNOS activity such that, when b-catenin is absent, basal eNOS
activity/Ser1177 phosphorylation is increased and is unable to increase
further in response to standard agonists (adenosine and histamine). We
also show for the first time that NO, derived either from eNOS or ex-
ogenously, inducesb-catenin translocation to the nucleus with resultant
effects on gene transcription and endothelial function, in particular with
regard to angiogenesis.
In situ proximity ligation assay revealed a pattern of co-localization of
eNOS andb-catenin predominantly close to cell borders, which may be
consistent with localization to caveolae. Both proteins are known to
associate with caveolin-133– 35 and this newly identified interaction
between eNOS and b-catenin may indicate a novel signalling complex.
Caveolin-1 is a negative regulator of eNOS,36 and it is possible that
the inhibitory action of b-catenin on eNOS function may be mediated
through co-interaction with caveolin-1. This possibility deserves
further investigation in future work. Analysis of proximity ligation
assays also revealed that pharmacological activation of eNOS disrupts
the interaction with inhibitory b-catenin, thus permitting NO produc-
tion. This observation supports the concept that eNOS is subject to
allosteric regulation by b-catenin, and also warrants further study in
the future.
Our demonstration that NO-cGMP signalling induces nuclear trans-
location of b-catenin as well as downstream gene transcriptional
effects supports previous work revealing induction of b-catenin signal-
ling following activation of iNOS.6 Conversely, it has previously been
shown in colon carcinoma cells, where b-catenin is constitutively
active, that application of NO-acetylsalicylic acid reduces b-catenin
transcriptional activity due to an inhibitory action of NO on the inter-
action between b-catenin and TCF-4.37 This suggests that in neoplastic
cells, the communication between NO andb-catenin differs in compari-
son to contact-inhibited quiescent endothelial cells, where b-catenin
expression and localization is highly regulated.
NO has previously been shown to directly S-nitrosylate b-catenin.8
Although we found that application of an exogenous NO donor mim-
icked the effect of eNOS activation on b-catenin nuclear translocation,
which might be consistent with such a mechanism, we also found that
inhibition of sGC (with ODQ) prevented this translocation in response
to salbutamol; moreover, elevation of cGMP (with 8-bromo-cGMP or
sildenafil) promoted nuclear translocation of b-catenin. These data
suggest that the effect of eNOS activation or exogenous NO on
b-catenin translocation is mediated through cGMP elevation rather
than through direct NO-mediated S-nitrosylation of b-catenin, or
indeed translocation of b-catenin released from active eNOS. cGMP
exerts its intracellular signalling through activation of PKG. PKG has pre-
viously been reported to phosphorylate GSK-3b inhibiting its activity.25
We here show that activation of eNOS or exogenous application of
spermine NONOate, increases phosphorylation of GSK-3b and that
this is attenuated following inhibition of sGC or PKG. Although the
PKG inhibitor may have non-specific effects at higher concentrations,
the concentration used in this study is highly selective for PKG.38
Figure 5 NO-cGMP signalling results in the induction of b-catenin-dependent target genes. HUVECs were treated with LiCl (10 mmol/L), spermine
NONOate (NO; 10 mmol/L), or sildenafil (Sil; 100 nmol/L) for 12 h. Transcript levels of IL-8 (A) and cyclin D1 (B) were assessed by quantitative RT–
PCR using HPRT as a housekeeping gene and quantified using the DDCt method and shown relative to vehicle (*P, 0.05 vs. vehicle, one-way ANOVA
with repeated measures; n ¼ 4 per group for cyclin D1 and n ¼ 5 per group for IL-8).
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Figure 6 Loss of b-catenin impairs NO-cGMP-mediated migration and angiogenesis of mouse pulmonary endothelial cells. (A) Wild-type and
b-catenin2/2 MPECs were treated with spermine NONOate (NO; 10 mmol/L), 8-bromo-cGMP (cGMP; 10 mmol/L) or sildenafil (Sil; 100 nmol/L) or
vehicle (Veh) for 12 h, following which cell lysates were probed by western blotting for VEGF and results expressed as the densitometric ratio of VEGF
tob-actin (shown relative to wild-type vehicle; *P, 0.05 vs. vehicle, one-way ANOVAwith repeated measures; n ¼ 4 per group). (B) Following treatment
with these same agonists or with VEGF (50 ng/mL), wild-type and b-catenin2/2 MPECs were seeded onto Matrigel and tube formation assessed after 6 h
(*P, 0.05, **P, 0.01 vs. vehicle, one-way ANOVAwithout repeated measures; n ¼ 6–8 per group). (C) Mice were injected with Matrigel supplemented
with VEGF (upper image panels) or bFGF (lower image panels) containing either wild-type or b-catenin2/2 MPECs labelled with Vybrant dye (green).
Matrigel plugs were excised after 7 days, cryosectioned and immunostained with antibodies against CD31 (red) and mounted in DAPI (blue) and
imaged using a confocal microscope (scale bar shows 50 mm). Results are expressed as the percentage of CD31-positive Vybrant-labelled MPECs com-
pared with the total number of CD31-positive cells within four randomly selected fields of view per plug (n ¼ 4 in each group; *P, 0.05 vs. wild-type
MPECs, unpaired t-test).
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Our results are therefore consistent with NO, derived either from
eNOS or from an exogenously applied NO donor, leading to sGC/
cGMP/PKG activation with resultant GSK-3b inhibition and thereby
activation and stabilization of b-catenin through a decrease in its
phosphorylation (summarized in Figure 7).
Many Ca2+-elevating eNOS agonists, such as histamine and thrombin,
increase vascular permeability through disruption of the VE-cadherin/
b-catenin complex.39,40 A recent study reported that exposure of
microvascular endothelial cells to histamine resulted in increased
levels of b-catenin in the nucleus.41 Similarly, stimulation with thrombin
has also been found to promote nuclear translocation of b-catenin
with consequent changes in gene expression.42 Consistent with these
findings, our study has shown that histamine and thrombin induce
b-catenin nuclear translocation, apparently through increasing intracel-
lular Ca2+. However, this occurs independently of any effects of hista-
mine and thrombin on eNOS activity or NO generation, since
L-NAME co-incubation did not alter the effect of histamine or thrombin
(unlike that of adenosine or salbutamol) onb-catenin nuclear transloca-
tion. It is possible that the nuclear translocation of b-catenin seen with
these agents occurs secondary to nuclear translocation of associated
eNOS. However, translocation is more likely to occur from cytosolic
b-catenin (due to an increase in stabilization as a consequence of inhib-
ition of the destruction complex) rather than plasmalemmal (and hence
eNOS-associated) b-catenin, since we found no obvious changes in
plasmalemmal distribution of b-catenin following 2.5 min treatment,
although relocation from this compartment cannot be ruled out.
On the other hand, NO-mediated translocation of b-catenin to the
nucleus does appear to result in transcriptional activation. Our data
demonstrate that activation of NO-cGMP signalling using either an
NO donor (spermine NONOate) or sildenafil, which inhibits cGMP
phosphodiesterases and thereby elevates cGMP, results in the expres-
sion of b-catenin/TCF target genes, namely IL-8 and cyclin D1, which
are important in regulating angiogenesis and proliferation. NO is well
documented to modulate gene regulation at the transcriptional level
in endothelial cells.43 –45 This has been described as occurring through
cGMP-mediated activation of transcription factors [in particular activat-
ing protein-1 (AP-1), cyclic AMPresponsiveelement binding protein and
early growth response protein-1] and through S-nitrosylation of tran-
scription factors (in particular NF-kB, hypoxia-inducible factor-1,
AP-1, nuclear factor-erythroid 2 p45-related factor 2, zinc finger tran-
scription factors and heterogeneous nuclear ribonucleoproteins), as
reviewed recently.46 Our data define a novel hitherto unrecognized
mechanism by which NO regulates gene expression, namely through
cGMP-dependent b-catenin nuclear translocation.
NO-cGMP signalling plays a key role in VEGF-induced angiogen-
esis,28–30 and it has been shown previously that angiogenesis and
wound healing are impaired in eNOS-deficient mice.47 We provide evi-
dence here that b-catenin is also required for NO-driven angiogenesis.
Endothelial cells lacking theb-catenin gene exhibited reduced expression
of VEGF in response to exogenously applied NO or elevation of cGMP.
These cells also exhibited attenuated angiogenic and migratory responses
to exogenous NO or to increased cGMP, as well as to VEGF (which
requires eNOS/NO signalling). On the other hand, angiogenic responses
to the NO-independent pro-angiogenic stimulus bFGF30 were intact in
these cells. In vivo capillary formation by b-catenin2/2 MPECs was also
attenuated in VEGF-supplemented Matrigel plugs when compared with
capillary formation by wild-type MPECs, while there was no difference
between these two cell types in Matrigel supplemented with bFGF.
These data support the observation that b-catenin is required to
mediate the pro-angiogenic effects of NO-cGMP signalling.
In conclusion, we have found in endothelial cells thatb-catenin associ-
ates with eNOS under basal conditions, and that eNOS activation leads
to b-catenin translocation to the nucleus through a cGMP-dependent
mechanism with resultant effects on gene transcriptionand downstream
functional responses, specifically as regards angiogenesis. We have also
shown that b-catenin acts as an endogenous negative regulator of
eNOS. Our findings provide novel evidence of bidirectional cross-talk
and regulation between the NO-cGMP and the b-catenin signalling
systems.
Supplementary material
Supplementary Material is available at Cardiovascular Research online.
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